Total Payments
$4,479
2024 Payments
$427.05
Companies
46
Transactions
303
Medicare Patients
4,444
Medicare Billing
$564,746
Payment Breakdown by Category
Food & Beverage$4,479 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $4,479 | 303 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $642.59 | 40 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $596.91 | 43 | $0 (2024) |
| ABBVIE INC. | $501.96 | 31 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $458.06 | 35 | $0 (2021) |
| Ferring Pharmaceuticals Inc. | $256.58 | 17 | $0 (2020) |
| Takeda Pharmaceuticals U.S.A., Inc. | $237.38 | 14 | $0 (2022) |
| PFIZER INC. | $156.66 | 11 | $0 (2024) |
| Daiichi Sankyo Inc. | $131.62 | 9 | $0 (2018) |
| AstraZeneca Pharmaceuticals LP | $129.18 | 9 | $0 (2020) |
| Kowa Pharmaceuticals America, Inc. | $117.26 | 9 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $427.05 | 26 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($176.94) |
| 2023 | $352.19 | 17 | AbbVie Inc. ($166.82) |
| 2022 | $134.23 | 9 | Celgene Corporation ($53.57) |
| 2021 | $283.26 | 22 | AbbVie Inc. ($141.54) |
| 2020 | $322.38 | 23 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($83.75) |
| 2019 | $981.24 | 69 | Takeda Pharmaceuticals U.S.A., Inc. ($156.07) |
| 2018 | $897.36 | 68 | Merck Sharp & Dohme Corporation ($172.46) |
| 2017 | $1,081 | 69 | Novo Nordisk Inc ($347.96) |
All Payment Transactions
303 individual payment records from CMS Open Payments — Page 1 of 13
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/04/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $17.27 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/27/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $16.61 | General |
| Category: Gastroenterology | ||||||
| 11/06/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $16.90 | General |
| Category: Gastroenterology | ||||||
| 10/16/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $16.78 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/11/2024 | Olympus America Inc. | EVIS X1 VIDEO SYSTEM CENTER (Device) | Food and Beverage | In-kind items and services | $22.18 | General |
| Category: Gastroenterology | ||||||
| 09/18/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $17.28 | General |
| Category: IMMUNOLOGY | ||||||
| 08/15/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $17.47 | General |
| Category: Diabetes | ||||||
| 08/14/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $3.67 | General |
| Category: Gastroenterology | ||||||
| 07/24/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $21.50 | General |
| Category: Immunology | ||||||
| 07/24/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $14.33 | General |
| Category: Gastroenterology | ||||||
| 07/17/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $23.79 | General |
| Category: Gastroenterology | ||||||
| 06/19/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $17.00 | General |
| Category: Gastroenterology | ||||||
| 06/17/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Food and Beverage | Cash or cash equivalent | $17.80 | General |
| Category: Oncology / Rare Diseases | ||||||
| 06/12/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $16.99 | General |
| Category: Gastroenterology | ||||||
| 06/06/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $14.19 | General |
| Category: Gastroenterology | ||||||
| 05/01/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $16.52 | General |
| Category: Gastroenterology | ||||||
| 04/17/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $13.43 | General |
| Category: Gastroenterology | ||||||
| 04/03/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $15.82 | General |
| Category: Gastroenterology | ||||||
| 03/20/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), SIMPONI, SIMPONI ARIA | Food and Beverage | In-kind items and services | $20.07 | General |
| Category: Immunology | ||||||
| 03/07/2024 | Micro-tech Endoscopy USA, Inc. | ABC Balloons (Device) | Food and Beverage | In-kind items and services | $23.03 | General |
| Category: GI Endoscopy | ||||||
| 02/12/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $13.79 | General |
| Category: GASTROENTEROLOGY | ||||||
| 02/07/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $7.69 | General |
| Category: Gastroenterology | ||||||
| 02/01/2024 | Braintree Laboratories, Inc. | SUFLAVE (Drug) | Food and Beverage | In-kind items and services | $16.59 | General |
| Category: GI COLON PREP | ||||||
| 01/31/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $13.84 | General |
| Category: IMMUNOLOGY | ||||||
| 01/17/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $16.32 | General |
| Category: Neuroscience | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 1,016 | 1,423 | $536,990 | $146,063 |
| 2022 | 17 | 1,245 | 1,706 | $600,546 | $163,358 |
| 2021 | 14 | 1,156 | 1,474 | $482,359 | $141,105 |
| 2020 | 14 | 1,027 | 1,429 | $412,888 | $114,219 |
Total Patients
4,444
Total Services
6,032
Medicare Billing
$564,746
Procedure Codes
58
All Medicare Procedures & Services
58 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 371 | 706 | $257,218 | $70,022 | 27.2% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 218 | 218 | $86,546 | $31,000 | 35.8% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 61 | 61 | $46,116 | $9,310 | 20.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 64 | 64 | $35,264 | $8,580 | 24.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 49 | 115 | $27,600 | $7,812 | 28.3% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 42 | 43 | $22,403 | $4,141 | 18.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 44 | 47 | $11,609 | $3,285 | 28.3% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 15 | 15 | $9,480 | $2,951 | 31.1% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 11 | 11 | $10,516 | $2,378 | 22.6% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2023 | 13 | 14 | $8,862 | $2,366 | 26.7% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 21 | 22 | $9,878 | $2,270 | 23.0% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 17 | 17 | $6,188 | $1,106 | 17.9% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 90 | 90 | $5,310 | $842.93 | 15.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 353 | 692 | $251,196 | $69,501 | 27.7% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 213 | 213 | $84,561 | $31,127 | 36.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 96 | 188 | $45,120 | $11,434 | 25.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 72 | 72 | $39,672 | $8,697 | 21.9% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 66 | 67 | $39,509 | $6,831 | 17.3% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 56 | 58 | $26,042 | $6,616 | 25.4% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 50 | 50 | $37,800 | $6,315 | 16.7% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2022 | 21 | 21 | $12,640 | $3,867 | 30.6% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 18 | 18 | $17,208 | $3,646 | 21.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 47 | 54 | $13,338 | $3,644 | 27.3% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2022 | 17 | 17 | $10,760 | $3,284 | 30.5% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2022 | 42 | 42 | $3,108 | $2,879 | 92.6% |
About Dr. Robert Ruffini, M.D
Dr. Robert Ruffini, M.D is a Gastroenterology healthcare provider based in West Orange, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1407920408.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Ruffini, M.D has received a total of $4,479 in payments from pharmaceutical and medical device companies, with $427.05 received in 2024. These payments were reported across 303 transactions from 46 companies. The most common payment nature is "Food and Beverage" ($4,479).
As a Medicare-enrolled provider, Ruffini has provided services to 4,444 Medicare beneficiaries, totaling 6,032 services with total Medicare billing of $564,746. Data is available for 4 years (2020–2023), covering 58 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location West Orange, NJ
- Active Since 11/20/2006
- Last Updated 08/05/2010
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1407920408
Products in Payments
- XIFAXAN (Drug) $575.47
- Victoza (Drug) $348.35
- JANUVIA (Drug) $255.72
- Ozempic (Drug) $207.35
- LINZESS (Drug) $185.73
- HUMIRA (Biological) $156.25
- CLENPIQ (Drug) $138.80
- DIFICID (Drug) $129.87
- Livalo (Drug) $117.26
- RINVOQ (Biological) $115.38
- Entyvio (Biological) $114.66
- FARXIGA (Drug) $114.18
- ZEPOSIA (Drug) $110.70
- PREPOPIK (Drug) $103.17
- INFLECTRA (Biological) $84.67
- Humira (Biological) $78.49
- Amitiza (Drug) $76.91
- INJECTAFER (Drug) $76.46
- ENTYVIO (Biological) $56.55
- Movantik (Drug) $55.16
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in West Orange
Dr. Alexander Perelman, D.o, D.O
Gastroenterology — Payments: $99,250
Gastroenterology $99,250
Robert Schuman, Md, MD
Gastroenterology — Payments: $44,812
Gastroenterology $44,812
Matthew Askin, M.d, M.D
Gastroenterology — Payments: $14,388
Gastroenterology $14,388
Dr. Lawrence Rosenthal, M.d, M.D
Gastroenterology — Payments: $11,431
Gastroenterology $11,431
Dr. Andrew Stefaniwsky, M.d, M.D
Gastroenterology — Payments: $6,822
Gastroenterology $6,822
William Sloan, M.d, M.D
Gastroenterology — Payments: $4,911
Gastroenterology $4,911